Tag #Long-Acting Injection

Showing 1 to 4 of 4 results

pt.euronews.com

🌐 85% Global Worthiness

Aug 12, 16:19

Weekly Parkinson's Injection Offers Hope for Millions

Australian scientists created a weekly injection combining Levodopa and Carbidopa to treat Parkinson's disease, improving adherence for the 10 million+ sufferers globally, with men affected 1.5 times more often than women.

Weekly Parkinson's Injection Offers Hope for Millions

Australian scientists created a weekly injection combining Levodopa and Carbidopa to treat Parkinson's disease, improving adherence for the 10 million+ sufferers globally, with men affected 1.5 times more often than women.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key challenges associated with current Parkinson's medication, and how does the new injection address these challenges?

The new injection addresses the significant challenge of medication adherence in Parkinson's patients, where nearly 50% fail to take prescribed medication. Missed doses severely impact daily life, hindering activities and increasing fall risks. The weekly injection aims to mitigate these issues, offering a more convenient and potentially life-changing treatment option.

sueddeutsche.de

🌐 90% Global Worthiness

Nov 28, 07:08

Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges

A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.

Semiannual HIV Injection Shows High Efficacy, Poses Access Challenges

A Phase 3 trial shows Lenacapavir, a semiannual HIV prevention injection, is highly effective and comparable to daily Truvada, offering improved adherence and reducing stigma in high-prevalence regions, but its high cost poses a global access challenge.

Progress

40% Bias Score

ShareSaveArticle

12345678

Previous 1 of 8 Next

What are the key challenges and opportunities in ensuring equitable access to Lenacapavir globally?

Lenacapavir's superior convenience addresses the challenges of daily PrEP adherence, particularly the social stigma in high-HIV-prevalence regions where daily pill use may lead to social ostracism. The comparable efficacy to Truvada, along with the twice-yearly injection schedule, positions Lenacapavir as a transformative advancement in HIV prevention.

elpais.com

🌐 85% Global Worthiness

Mar 11, 22:13

Annual Lenacapavir Injection Shows Promise in HIV Prevention

A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.

Annual Lenacapavir Injection Shows Promise in HIV Prevention

A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How might the accessibility and cost of lenacapavir impact its global rollout and effectiveness?

The study's positive results build on previous research showing lenacapavir's preventive potential with twice-yearly subcutaneous injections. This new annual intramuscular injection option could overcome adherence challenges associated with daily oral PrEP medications like Truvada. However, the high cost, around \$20,000 annually in the US, presents a significant barrier to accessibility.

faz.net

🌐 85% Global Worthiness

Nov 28, 19:07

Injectable HIV PrEP Shows 96% Infection Reduction

Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.

Injectable HIV PrEP Shows 96% Infection Reduction

Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.

Progress

48% Bias Score

ShareSaveArticle

12345678

Previous 1 of 8 Next

How does Lenacapavir's administration method improve upon existing HIV PrEP strategies and what are the immediate implications?

Lenacapavir, administered as an injection every six months, offers comparable efficacy to daily Truvada tablets for HIV pre-exposure prophylaxis (PrEP). This reduces the frequency of medication and eliminates the stigma associated with daily pill-taking, particularly in high-HIV prevalence areas.

Showing 1 to 4 of 4 results